Savant Capital LLC Boosts Stock Position in Zoetis Inc. (NYSE:ZTS)

Savant Capital LLC lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 5.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,271 shares of the company’s stock after buying an additional 313 shares during the period. Savant Capital LLC’s holdings in Zoetis were worth $1,022,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. AMF Tjanstepension AB grew its holdings in shares of Zoetis by 23.4% during the 3rd quarter. AMF Tjanstepension AB now owns 105,376 shares of the company’s stock valued at $20,594,000 after purchasing an additional 20,001 shares during the last quarter. Exchange Traded Concepts LLC boosted its position in Zoetis by 4,582.9% during the third quarter. Exchange Traded Concepts LLC now owns 1,639 shares of the company’s stock valued at $320,000 after buying an additional 1,604 shares during the period. Creative Planning grew its stake in shares of Zoetis by 8.6% during the third quarter. Creative Planning now owns 90,401 shares of the company’s stock valued at $17,663,000 after buying an additional 7,170 shares during the last quarter. Asset Dedication LLC increased its holdings in shares of Zoetis by 10.4% in the third quarter. Asset Dedication LLC now owns 1,296 shares of the company’s stock worth $253,000 after buying an additional 122 shares during the period. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its stake in shares of Zoetis by 18.8% in the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 8,821 shares of the company’s stock valued at $1,723,000 after acquiring an additional 1,393 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. UBS Group assumed coverage on Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. Piper Sandler lowered their price target on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a report on Monday, February 10th. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Stifel Nicolaus lowered their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Finally, Barclays raised their target price on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $214.90.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares of the company’s stock, valued at $2,757,196.26. The trade was a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Zoetis Stock Performance

Shares of Zoetis stock opened at $157.54 on Friday. The business has a fifty day simple moving average of $168.89 and a two-hundred day simple moving average of $178.98. The firm has a market capitalization of $71.08 billion, a P/E ratio of 29.61, a P/E/G ratio of 2.77 and a beta of 0.90. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.53.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. On average, equities analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.27%. The ex-dividend date is Monday, April 21st. Zoetis’s payout ratio is 37.59%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.